Phase II study of Iressa with/without concurrent chemoradiotherapy in patients with advanced non-nasopharyngeal head and neck carcinoma and to study the effect of Iressa (ZD1839) [gefitinib] on tumour gene expression profiles

Trial Profile

Phase II study of Iressa with/without concurrent chemoradiotherapy in patients with advanced non-nasopharyngeal head and neck carcinoma and to study the effect of Iressa (ZD1839) [gefitinib] on tumour gene expression profiles

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2007

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2007 Status changed from in progress to completed.
    • 20 Nov 2006 Status change
    • 02 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top